<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20210306050605N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-04-20</date_registration>
      <primary_sponsor>Tabriz University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of tetracycline gel and gel containing mesoporous silica nanoparticles loaded with tetracycline on reducing microbial infection at the junction of implant and abutment</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the antibacterial effect of tetracycline gel and gel containing mesoporous silica nanoparticles loaded with tetracycline in the gingival sulcus fluid at the site of junction between the implant and the abutment</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>15</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/54854</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Basic scienece.</study_design>
      <phase>N/A</phase>
      <hc_freetext>periodontitis.</hc_freetext>
      <i_freetext>Intervention 1: The first intervention group: first implant.  Material used in the first intervention group:Tetracycline gel (with a water base containing one percent tetracycline and two percent gel) Frequency, method and duration of use: In the uncovering session, the gel is placed inside the implant with a syringe and the healing abutment is closed. Then, in three sessions: implantation, impression (10 days after the healing abutment closure session), prosthesis delivery (15 days after the impression session) and one month after prosthesis delivery, patients are sampled. Sampling intervals will be the same for all patients. To prepare the gel, carbomer 940 gel (drug grade, product of Bismuth Company) is used. Intervention 2: Intervention group: the second implant.Gel containing tetracycline-loaded mesoporous silica nanoparticles (with a mean particle size of 100 nm and needle morphology) containing tetracycline gel). Frequency, method and duration of use: In the uncovering session, the gel is placed inside the implant with a syringe and the healing abutment is closed. Then, in three sessions: implantation, impression (10 days after the healing abutment closure session), prosthesis delivery (15 days after the impression session) and one month after prosthesis delivery, patients are sampled. Sampling intervals will be the same for all patients. A summary of how mesoporous silica nanoparticles are prepared and how tetracycline is loaded into them is that the mixture of surfactant (CTAB), distilled water and sodium hydroxide (NaOH) is stirred on the stirrer for up to 80 ° C for 30 minutes. The pH of the solution is then adjusted to 12.2. In the next step, tetraethyl orthosilica (Sigma Aldrich brand) is added to the solution immediately under a 550 RPM stirrer. A white precipitate is deposited. The ambient temperature of the solution is maintained at 80 ° for two hours. Tetracycline (a product of Sigma) is dissolved in ethanol. The prepared nanoparticle powder is added to the drug solution. The resulting mixture is gently stirred at room temperature on the stirrer for 48 hours in the dark. The product is mesoporous silica nanoparticles contains tetracycline. Intervention 3: Control group:  the third implant.No substance is used.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Fereydoon Parnia</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht ST, Daneshgah Ave, Tabriz university of medical sciencesا</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>+98 41 3335 3161</telephone>
        <email>fereydoon.parnia@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Solmaz Maleki Dizaj</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Golgasht ST, Daneshgah Ave, Tabriz university of medical sciences</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>5166614766</zip>
        <telephone>009833353161</telephone>
        <email>maleki.s.89@gmail.com</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1- Having at least 3 implants in one jaw
2- Having a minimum age of 18 years
3- The depth of the probe around the implant is between 1-3 mm (height of the abutment heel inside the gingiva is maximum 3 mm)
4- Possibility of placing zirconia crown with upper gingival margin
5- At least 4 months have passed since the extraction of the replacement teeth.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1- Pregnant and lactating women
2- Patients receiving antibiotics in the last 6 months
3- Having any systemic disease such as diabetes that affects oral health
4- Addiction to drugs, cigarettes or alcohol
5-History of allergy to tetracycline
6- Based on the flowchart of diagnosis of covid 19 in the levels of outpatient services for definite people with coronary heart disease and suspected of it (1. History of dry cough or chills or sore throat with shortness of breath with or without fever, which can be justified by another etiological factor 2. A patient with fever or respiratory symptoms (whatever the severity): A. Have a history of close contact with a probable / definite case of covid 19 within 14 days prior to the onset of symptoms. Health personnel)
7- Patients with bone thickness less than 5 mm in cbct and patients need graft and bone reconstruction
8- Presence of periodontal disease in other</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M27.62</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Post-osseointegration biological failure of dental implant</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>The first intervention group: first implant.  Material used in the first intervention group:Tetracycline gel (with a water base containing one percent tetracycline and two percent gel) Frequency, method and duration of use: In the uncovering session, the gel is placed inside the implant with a syringe and the healing abutment is closed. Then, in three sessions: implantation, impression (10 days after the healing abutment closure session), prosthesis delivery (15 days after the impression session) and one month after prosthesis delivery, patients are sampled. Sampling intervals will be the same for all patients. To prepare the gel, carbomer 940 gel (drug grade, product of Bismuth Company) is used.</i_keyword>
      <i_keyword>Intervention group: the second implant.Gel containing tetracycline-loaded mesoporous silica nanoparticles (with a mean particle size of 100 nm and needle morphology) containing tetracycline gel). Frequency, method and duration of use: In the uncovering session, the gel is placed inside the implant with a syringe and the healing abutment is closed. Then, in three sessions: implantation, impression (10 days after the healing abutment closure session), prosthesis delivery (15 days after the impression session) and one month after prosthesis delivery, patients are sampled. Sampling intervals will be the same for all patients. A summary of how mesoporous silica nanoparticles are prepared and how tetracycline is loaded into them is that the mixture of surfactant (CTAB), distilled water and sodium hydroxide (NaOH) is stirred on the stirrer for up to 80 ° C for 30 minutes. The pH of the solution is then adjusted to 12.2. In the next step, tetraethyl orthosilica (Sigma Aldrich brand) is added to the solution immediately under a 550 RPM stirrer. A white precipitate is deposited. The ambient temperature of the solution is maintained at 80 ° for two hours. Tetracycline (a product of Sigma) is dissolved in ethanol. The prepared nanoparticle powder is added to the drug solution. The resulting mixture is gently stirred at room temperature on the stirrer for 48 hours in the dark. The product is mesoporous silica nanoparticles contains tetracycline.</i_keyword>
      <i_keyword>Control group:  the third implant.No substance is used.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The Measurement of the amount of bacteria after placing tetracycline gel and gel containing tetracycline-loaded nanoparticles in the implant for three times. Timepoint: 10 days 15 days 30 days after placing the sample. Method of measurement: Bacterial colony counting method.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tabriz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-02-28</approval_date>
        <contact_name>Ethics committee of Tabriz university of medical sciences</contact_name>
        <contact_address>Golgasht st, Daneshgah Ave, Tabriz university of medical sciences Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
